297 related articles for article (PubMed ID: 24382690)
1. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J; Xie Q; Tan D; Ning Q; Niu J; Bai X; Fan R; Chen S; Cheng J; Yu Y; Wang H; Xu M; Shi G; Wan M; Chen X; Tang H; Sheng J; Dou X; Shi J; Ren H; Wang M; Zhang H; Gao Z; Chen C; Ma H; Jia J; Hou J
Hepatology; 2014 Apr; 59(4):1283-92. PubMed ID: 24382690
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.
Zhang Y; Lian JQ; Li Y; Wang JP; Huang CX; Bai XF; Wang JP
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):814-9. PubMed ID: 23406845
[TBL] [Abstract][Full Text] [Related]
4. Real-world application of the roadmap model in chronic hepatitis B patients with telbivudine therapy.
Yu HC; Lin KH; Hsu PI; Tsay FW; Wang HM; Tsai TJ; Lai KH
Clin Ther; 2013 Sep; 35(9):1386-99. PubMed ID: 24054706
[TBL] [Abstract][Full Text] [Related]
5. Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Liang X; Cheng J; Sun Y; Chen X; Li T; Wang H; Jiang J; Chen X; Long H; Tang H; Yu Y; Sheng J; Chen S; Niu J; Ren H; Shi J; Dou X; Wan M; Jiang J; Xie Q; Shi G; Ning Q; Chen C; Tan D; Ma H; Sun J; Jia J; Zhuang H; Hou J
J Gastroenterol Hepatol; 2015 Apr; 30(4):748-55. PubMed ID: 25352300
[TBL] [Abstract][Full Text] [Related]
6. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
7. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
8. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B.
Piratvisuth T; Komolmit P; Tanwandee T; Sukeepaisarnjaroen W; Chan HL; Pessôa MG; Fassio E; Ono SK; Bessone F; Daruich J; Zeuzem S; Cheinquer H; Pathan R; Dong Y; Trylesinski A
PLoS One; 2013; 8(2):e54279. PubMed ID: 23390496
[TBL] [Abstract][Full Text] [Related]
9. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of telbivudine treatment for hepatitis B e antigen-positive chronic hepatitis B patients with poor response to adefovir dipivoxil.
Li Y; Zhang Y; Wang JP; Lian JQ; Bai XF
J Viral Hepat; 2013 Apr; 20 Suppl 1():46-51. PubMed ID: 23458524
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.
Chan HL; Heathcote EJ; Marcellin P; Lai CL; Cho M; Moon YM; Chao YC; Myers RP; Minuk GY; Jeffers L; Sievert W; Bzowej N; Harb G; Kaiser R; Qiao XJ; Brown NA;
Ann Intern Med; 2007 Dec; 147(11):745-54. PubMed ID: 17909201
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
15. [Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].
Ling N; Zhou Z; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2007 May; 15(5):346-9. PubMed ID: 17524266
[TBL] [Abstract][Full Text] [Related]
16. Serum HBV DNA level at week 12 is superior to viral response at week 24 in predicting long-term treatment outcome of telbivudine for chronic hepatitis B patients.
Lü W; Yang HH; Fan YM; Li T; Zhang LF; Mui C; Fan HW; Zhou BT; Liu ZY; Ng H; Liu XQ
Chin Med J (Engl); 2013 Jun; 126(12):2333-6. PubMed ID: 23786949
[TBL] [Abstract][Full Text] [Related]
17. Telbivudine plus tenofovir in combination therapy in patients with chronic hepatitis B infection--an Indian experience.
Panda C
J Assoc Physicians India; 2013 Nov; 61(11):785-8. PubMed ID: 24974488
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
Marcellin P; Chang TT; Lim SG; Sievert W; Tong M; Arterburn S; Borroto-Esoda K; Frederick D; Rousseau F
Hepatology; 2008 Sep; 48(3):750-8. PubMed ID: 18752330
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
20. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
